IMPORTANCE Cardiovascular disease (CVD), the leading cause of mortality and morbidity in the United States, may be potentially preventable with statin therapy.
dations on statin therapy for prevention of CVD in adults 40 years and older without prior cardiovascular events. 10 Although previous USPSTF recommendations 11 addressed screening for lipid disorders, the USPSTF has not addressed selection of patients for preventive therapy or statin selection and treatment strategies.
Methods

Scope of the Review
Using established methods, 12 the USPSTF determined the scope and key questions for this review ( Figure 1 ). This review was conducted as a subcategory of the lipid disorders in adults topic. The final research plan was posted on the USPSTF website prior to conducting the review. 13 Detailed methods are available in the full evidence report available at http://www.uspreventiveservicestaskforce .org/Page/Document/final-evidence-review149/statin-use-in -adults-preventive-medication1.
Data Sources and Searches
A research librarian searched the Cochrane Central Register of Controlled Trials (from 1991), the Cochrane Database of Systematic Reviews (from 2005), and Ovid MEDLINE (from 1946) to June 2016 for English-language publications (eAppendix 1 in the Supplement), and reference lists. After the draft report was posted for public comment and peer review, the search was updated in June 2016 and 1 additional trial was added. 14 
Study Selection
Two reviewers independently evaluated each study on the basis of predefined criteria at the abstract and full-text review levels (eTable 1 in the Supplement). The population of interest was adults 40 years and older without prior CVD events. Studies were limited to those in which fewer than 10% of the participants had prior CVD events to include only trials that predominantly enrolled the population of interest. We included randomized trials of statin therapy vs placebo or no statin and assessed all-cause mortality, coronary heart disease, stroke-related morbidity or mortality, or harms of treatment (including muscle injury, cognitive loss, incident diabetes, and hepatic injury). We also included studies of statin treatment adjusted to achieve target low-density lipoprotein cholesterol (LDL-C) levels vs fixed-dose or other treatment strategies and studies that evaluated effects of statin therapy intensity on benefits and harms. For diabetes incidence, large cohort and case-control studies of statin use vs nonuse were also included. The selection of literature is summarized in Figure 2 .
Data Abstraction and Quality Assessment
One investigator abstracted details about the study design, patient population, setting, screening method, interventions, analysis, and results, and a second investigator checked the abstracted data. Two investigators independently applied criteria developed by the USPSTF 12 to rate the quality of each study as good, fair, or poor (eTable 2 in the Supplement). Discrepancies were resolved through consensus.
Data Synthesis and Analysis
Meta-analyses were conducted to calculate risk ratios (RRs) for statins vs placebo using the Dersimonian-Laird random-effects model with Review Manager version 5.2 (Cochrane Collaboration Nordic Cochrane Centre). Statistical heterogeneity was assessed with the I 2 statistic. 15 When statistical heterogeneity was present (defined as I 2 > 30%), sensitivity analysis was performed with the profile likelihood method using Stata version 10.1 (StataCorp). 16 Additional sensitivity and stratified analyses were performed based on study quality, exclusion of trials that enrolled patients with prior CVD events, duration of follow-up, intensity of statin therapy, 4 mean total cholesterol and LDL-C levels at baseline, and whether the trial was stopped early. For analyses with 10 or more trials, funnel plots were constructed to detect small sample effects.
17
The aggregate internal validity (quality) of the body of evidence was assessed for each key question using methods developed by the USPSTF (eTable 3 in the Supplement), 12 based on the number, quality, and size of studies; consistency of results between studies; and directness of evidence.
Results
Study Characteristics
Nineteen randomized trials ( Table 2 ) assessed the effects of statins vs placebo or no statin on health outcomes in adults without prior CVD events (full list of primary and secondary publications, including study acronyms, are reported in eAppendix 2 in the Supplement). 14, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] The trials enrolled between 95 and 17 802 study participants (total sample, 71 344 participants). Mean ages ranged from 51 to 66 years. Duration of follow-up ranged from 6 months to 6 years. All trials enrolled patients at increased cardiovascular risk. In 6 trials, the main criterion for enrollment was presence of dyslipidemia 19, 24, 30, 31, 33, 35 ; in 3 trials, early cerebrovascular disease 1 8, 2 5, 32 ; in 4 trials, diabetes 2 were excluded (eTable 5 in the Supplement). Funnel plot asymmetry was not observed for outcomes reported in at least 10 trials (eFigures 5-9 in the Supplement).
Key Question 1b. What are the benefits of statin treatment to achieve target LDL-C levels vs other treatment strategies?
No trial directly compared statin treatment titrated to attain target cholesterol levels vs fixed-dose treatment. There were no clear differences in estimates between 3 trials 18,19,31 of statins vs placebo that permitted limited dose titration (RR for cardiovascular or the metabolic syndrome (2 trials).
20,29
Sex and age were the most commonly reported subgroups. For composite cardiovascular outcomes, relative risk estimates were very similar for men and women in 5 trials (eTable 6 in the Supplement). 14, 19, 26, 29, 31 In the ASCOT-LLA trial, the hazard ratio (HR) for nonfatal myocardial infarction plus fatal coronary heart disease was 0. 
Discussion
In adults at increased cardiovascular risk but without prior cardiovascular events, statin therapy was associated with reduced risk of clinical outcomes vs placebo, based on 19 trials with 6 months to 6 years of follow-up (summarized in Table 3 , and other individual and composite cardiovascular outcomes. Findings were generally robust in sensitivity and stratified analyses based on trial quality, follow-up duration, baseline lipid levels, exclusion of trials stopped early, and exclusion of trials with some (<10% of sample) patients with prior cardiovascular events. Adding the large HOPE-3 trial, 14 which was identified when the search was updated, also had little effect on findings. Based on pooled estimates, the NNT to prevent 1 death from any cause was 250 after 1 to 6 years, and to prevent 1 cardiovascular death was 233 after 2 to 6 years. However, the NNT varied in individual trials depending on factors such as the baseline risk of the population (eTable 7 in the Supplement) and the duration of follow-up (eTable 5 in the Supplement). These findings regarding benefits associated with statin therapy were generally consistent with findings from recent systematic reviews 46 Outcomes associated with statin use appeared to be similar in patient subgroups defined according to demographic and clinical characteristics. Few trials enrolled patients older than 75 years, and no trial reported results in this subgroup. Benefits of statins did not appear to be restricted to patients with severely elevated lipid levels, because similar effects were observed in subgroups stratified according to baseline levels. 21, 23, 26, 29 In a population without markedly elevated lipid levels (mean LDL-C, 128 mg/dL), the HOPE-3 trial found similar effects of statins among persons with and without elevated CRP levels. 14 Similarly, trials reported similar relative risk estimates in persons classified as having higher and lower assessed cardiovascular risk. 19, 29 Given similar relative risk estimates, the absolute benefits of statin therapy will be greater in populations at higher baseline risk. For example, in the JUPITER trial, the NNT to prevent 1 cardiovascular event was 94 in people younger than 70 years and 62 in those 70 years and older. 29 In the AFCAPS/TexCAPS trial, the absolute risk reduction for major cardiovascular events was 6.64 per 1000 person-years in persons with a 10-year risk greater than 20% and 3.29 per 1000 person-years in those with 10-year risk less than 20%.
50
This review found no evidence that statins were associated with increased risk of withdrawal because of adverse events, serious adverse events, cancer, or elevated liver enzyme levels vs placebo or no statin therapy. These findings are generally consistent with those from recent systematic reviews, some of which also included trials of statins for secondary prevention. In the JUPITER study, among patients with diabetes risk factors, 134 cardiovascular events were prevented for every 54 incident cases of diabetes, while among persons without diabetes risk factors, 86 cardiovascular events were prevented, with no incident diabetes.
41
Evidence for the association between statin use and cognitive harms was sparse but indicated no clear increase in risk. These findings are consistent with those from a recent systematic review of randomized trials and observational studies that found no adverse associations of statins with incidence of Alzheimer disease, dementia, or decreased scores on tests of cognitive performance.
52
No trial directly compared treatment with statins titrated to attain target cholesterol levels vs fixed-dose therapy, and only 3 18, 19, 31 of 18 trials permitted limited dose titration, with no clear differences compared with fixed-dose trials. There was also little direct evidence to determine effects of statin therapy intensity on outcomes, although there were no clear differences in effect estimates when placebocontrolled trials of statins were stratified according to the intensity of therapy. A meta-analysis of individual-patient data from 22 trials, including trials of patients with prior cardiovascular events, found an association between the degree of LDL-C lowering and reduced risk of clinical outcomes, potentially providing indirect evidence regarding the effects of statin intensity.
64
This review had limitations. The meta-analysis used the Dersimonian-Laird random-effects model to pool studies, which can result in overly narrow confidence intervals when heterogeneity is present, particularly when there are few studies. 16 However, when statistical heterogeneity was present, analyses were repeated using the profile likelihood method, which resulted in similar findings. We did not have access to individual-patient data. An individualpatient data meta-analysis found that the association between use of statins for primary prevention and all-cause mortality did not reach statistical significance (RR, 0.91 [95% CI, 0.83 to 1.01]) 46 but did not include the recently published, large HOPE-3 trial, 14 which reported results consistent with the pooled estimates in this review.
Because that meta-analysis had access to individual-patient data, the authors were able to include some trials that we excluded because more than 10% of the population had prior cardiovascular events. 65, 66 For trials in which less than 10% of patients had prior cardiovascular events, 20,30,34 it was also able to separately analyze the patients with no prior cardiovascular events. Excluding these trials from our analyses did not affect the findings. Direct evidence was unavailable or limited on effects of dose titration vs fixed-dose therapy or statin intensity on clinical outcomes. Therefore, this review primarily relied on analyses of placebo-controlled trials stratified according to the use of dose titration or statin intensity. The review also excluded non-English-language articles 67,68 and formally assessed for publication bias only when there were at least 10 studies. Graphical and statistical tests for publication bias are not recommended when there are fewer than 10 studies, because they can be misleading. 17 Drugs in the proprotein convertase subtilisin kexin 9 class were outside the scope of this review. Additionalresearchisneededtodirectlycompareeffectsofstatin therapy to target lipid levels vs fixed-dose therapy and higher-vs lower-intensitystatintherapy;tomoredefinitivelydeterminewhether statin therapy is associated with increased diabetes or cataract risk; and to determine how statin intensity affects risk. Research is needed to understand benefits and harms of statins in older persons and to compare effects of selection of patients for statin therapy based on global risk assessment scores vs presence of defined cardiovascular risk factors. The validation of cardiovascular risk assessment instruments (with some studies showing overestimation of risk) and research on effects of using newer risk factors to supplement traditional cardiovascular risk assessment is ongoing. 7, [69] [70] [71] [72] 
Conclusions
In adults at increased CVD risk but without prior CVD events, statin therapy was associated with reduced risk of all-cause and cardiovascular mortality and CVD events, with greater absolute benefits in patients at greater baseline risk.
